📇 Rhumatologue · CREPY EN VALOIS · (60) · Salarié

MME ISABELLE LOPEZ

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Praticien-chercheur
12 articles scientifiques publiés — formation continue solide
Disponibilité géographique
8 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
73.1 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 CREPY EN VALOIS (60)SalariéRPPS 10001486660

🇫🇷 Publications académiques françaises (2)

✨ Génération du profil synthétique IA en cours…

Publications académiques en France

Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas
2020
Article

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020

📚 150 citations🎯 RCR 7.13Top 4% NIH🩺 Clinique

Lire l'abstract Crossref ↓

PURPOSETo evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas (CSCCs).PATIENTS AND METHODSPatients, predominantly men, with their CSSCs’ immunohistochemically determined programmed cell death-ligand 1 (PD-L1) status determined (tumor proportion score threshold, 1%), received pembrolizumab (200 mg every 3 weeks). The primary endpoint was the 39-patient primary cohort’s objective response rate at week 15 (ORRW15). Secondary objectives were best ORR, overall survival (OS), progression-free survival (PFS), duration of response (DOR), safety, ORR according to PD-L1 status and health-related quality of life using Functional Assessment of Cancer Therapy–General (FACT-G) score. An 18-patient expansion cohort, recruited to power the study to evaluate the ORRW15difference between PD-L1+ and PD-L1– patients, was assessed for ORR, disease control rate, and safety, but not survival.RESULTSMedian age of all patients was 79 years. The primary cohort’s ORRW15was 41% (95% CI, 26% to 58%), including 13 partial and 3 complete responses. Best responses were 8 partial and 8 complete responses. At a median follow-up of 22.4 months, respective median PFS, DOR, and OS were 6.7 months, not reached, and 25.3 months, respectively. Pembrolizumab-related adverse events affected 71% of the patients, and 4 (7%) were grade ≥ 3. One death was related to rapid CSCC progression; another resulted from a fatal second aggressive head and neck squamous cell carcinoma diagnosed 15 weeks postinclusion. ORRW15for the entire population was 42%; it was significantly higher for PD-L1+ patients (55%) versus PD-L1– patients (17%; P = .02). Responders’ W15 total FACT-G score had improved ( P = .025) compared with nonresponders.CONCLUSIONFirst-line pembrolizumab monotherapy exhibited promising anti-CSCC activity, with durable responses and manageable safety. PD-L1 positivity appears to be predictive of pembrolizumab efficacy.

Impact of race and ethnicity on inflammatory bowel disease

The American journal of gastroenterology · 2005

📚 122 citations🎯 RCR 3.35Top 14% NIH

Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2006

📚 94 citations🎯 RCR 2.62Top 19% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract VC is an important clinical entity; however, very little information is available on its resolution. Induction and regression of calcitriol-induced VC was studied in 47 rats. After calcitriol withdrawal, there was a relatively rapid regression of VC mediated by an active cellular process. Introduction: Vascular calcifications (VCs) represent an important risk factor for cardiovascular death. Although VCs are prevalent in relevant diseases (e.g., chronic kidney disease, osteoporosis, diabetes), the reversibility of extraskeletal calcifications is an unresolved issue. This study was conducted to investigate (1) the in vivo effect of calcitriol on VC and (2) whether calcitriol-induced VC would regress after suppression of calcitriol treatment. Materials and Methods: The calcifying effect of calcitriol was studied in four groups of rats (n = 8) that received calcitriol (1 μg/kg, IP) for 2, 4, 6, and 8 days. The reversibility of VC was studied in three additional groups (n = 5) treated with 1 μg/kg of calcitriol for 8 days that were subsequently killed 1, 2, and 9 weeks after the last calcitriol dose. Aortic VC was assessed by histology and by quantification of aortic calcium and phosphorus content. The aortic wall was studied by histology and immunohistochemistry. Statistical analysis was performed by ANOVA and t-tests. Results: Calcitriol administration resulted in a time-dependent induction of VC, with aortic calcium and phosphorus being significantly increased at 6 and 8 days. Treatment with calcitriol for 8 days resulted in massive medial calcification of the aorta with a 10- to 30-fold increase in the aortic Ca and P content. After suppressing calcitriol administration, a progressive decrease in von Kossa staining and aortic Ca (from 32.8 ± 2.5 to 9.3 ± 1.8 mg/g of tissue, p &lt; 0.001) and P (from 11.9 ± 1.2 to 2.7 ± 1.8 mg/g of tissue, p = 0.001) content was evidenced. Histology of the aortic wall showed monocytes adhered to the aortic endothelium and macrophages involved in the reabsorption of calcium deposits. Conclusions: Our results show that calcitriol treatment induces time-dependent VC. After calcitriol withdrawal, VC regress rapidly with aortic calcium and phosphorus decreasing by 75% in the course of 9 weeks. An active cellular process seems to be involved in regression of VC.

Cookies & analyse de trafic

MME ISABELLE LOPEZ

Pourquoi vous devez consulter ce praticien

Publications académiques en France

Lieux de consultation(8)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (12) — classées par pathologie

Transversal8

Biothérapies non-anti-TNF1

Essai clinique1

JAK inhibiteurs1

Qualité de vie / PROMs1

Sjögren1

Partager cette fiche